Gossamer Bio Inc (GOSS NASDAQ) stock market data APIs
$2.3129
-0.05(-2.2%)
as of November 6, 2025
Try our APIs with
free plan!
Gossamer Bio Inc Financial Data Overview
Price chart is built with
Anychart
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
Prev. Close
2.3129
Open
2.2663
High
2.4203
Low
2.2643
52 wk Range
0.6617-3.6
Market Cap
542 M
Shares Outstanding
229 M
Revenue
40 237 K
EPS
0
Beta
1.958
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Gossamer Bio Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Gossamer Bio Inc data using free add-ons & libraries
Get Gossamer Bio Inc Fundamental Data
Gossamer Bio Inc Fundamental data includes:
- Net Revenue: 40 237 K
- EBITDA: -145 286 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-06
- EPS/Forecast: -0.1887
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Gossamer Bio Inc News
New
Presenting on Emerging Growth Conference 87 Day 2 on October 23; Register to live stream
MIAMI, Oct. 22, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 87th Emerging Growth Conference on October 22 & 23, 2025. The ...
Presenting on Emerging Growth Conference 87 Day 1 on October 22. Register to live stream.
MIAMI, Oct. 21, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 87th Emerging Growth Conference on October 22 & 23, 2025. The ...
3 Biotech Stocks That Could More Than Triple if Their Trials Succeed
Biotech investing is often a high-risk, high-reward game, with clinical trial results capable of sending stocks soaring or plummeting. For investors willing to bet on scientific breakthroughs, these t...
Sector Update: Health Care Stocks Decline Premarket Thursday
Health care stocks were declining premarket Thursday, with the Health Care Select Sector SPDR Fund ( PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
